MarketPulse — Real-Time Financial News & Market Analysis

Artiva Biotherapeutics appoints veteran pharma executive Thad Huston as CFO with 30+ years experience, ahead of key FDA feedback and clinical data milestones.

Kyverna appoints two biotech executives to its board ahead of cell therapy commercialization. New directors bring expertise from Beam Therapeutics and Karuna Therapeutics.

Gabelli Funds hosts its 17th Annual Specialty Chemicals Symposium on March 19, 2026, bringing together industry executives and investors for discussions on market trends and strategic challenges.

Gentex approves $0.12 per share quarterly dividend for Q1 2026, payable April 22 to shareholders of record as of April 8.

Clene outlines 2026 regulatory milestones for ALS drug CNM-Au8, including FDA meeting, NDA submission, and Phase 3 trial, backed by $28 million funding.

Integer Holdings to present at three major healthcare investment conferences in March 2026, including Raymond James, Oppenheimer, and KeyBanc events.

Collate launches AI Studio with semantic intelligence platform enabling enterprises to deploy AI agents that accurately understand complex organizational data, addressing reliability concerns in enterprise AI.

Vistagen Therapeutics shareholders must file for lead plaintiff status by March 16, 2026 in securities fraud lawsuit alleging false statements and undisclosed risks.

Rogers launches GO Anywhere Plus, a satellite-IoT service for remote asset tracking across Canada, partnering with Geotab to extend fleet management beyond cellular coverage areas.

Rogers launches GO Anywhere Plus, a satellite IoT service for asset tracking in remote Canadian regions where cellular networks don't reach, partnering with Geotab.

Intel gains 1.40% in premarket trading after partnering with SambaNova Systems to integrate Xeon processors into AI systems, replacing AMD chips.

Buffett's core holdings—Apple, Coca-Cola, Chevron, Visa, Domino's—exemplify enduring wealth-creation through competitive advantages, consistent cash flows, and shareholder returns across economic cycles.

TopBuild acquires Johnson Roofing for $29M revenue, expanding commercial roofing services across Texas, Louisiana, and Oklahoma.

Treasury yields fell 25 basis points in a week on softer-than-expected inflation data, prompting investors to reassess rate expectations and reposition portfolios.

BWX Technologies beat Q4 expectations with strong nuclear and defense demand. The company's $7.3B backlog and optimistic 2026 guidance reflect robust market confidence.

CoreWeave's stock surged 140% with strong 133% sales growth, but the company faces profitability concerns, $19B debt, and dangerous customer concentration with two clients representing 77% of revenue.

Prediction markets give Nvidia 95% odds of beating earnings expectations Wednesday, buoyed by four consecutive quarters of surpassing estimates and strong AI/data center demand.

Global anti-snoring devices market projected to nearly double to $3.36 billion by 2033, driven by obesity, health awareness, and technological advances.

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.

Aquestive Therapeutics will report Q4 2025 results March 4 and hold investor call March 5, discussing financial performance and pipeline progress including Anaphylm™ development.